Background The understanding of ovarian cancer pathogenesis has recently shifted to
recognize distinct changes in how ovarian cancer histotypes are defined. Using the 2014 World …

PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–directed
chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple …

C-reactive protein is involved in ovarian carcinogenesis, and chronic inflammation may be
particularly implicated in the etiology of mucinous and endometrioid carcinomas. …

Multiple myeloma (MM) incidence, mortality, and survival vary by race and ethnicity, but the
causes of differences remain unclear. We investigated demographic, clinical, and molecular …

Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of
relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade ≥ 3 …

Background: The Deepwater Horizon Oil Spill (DHOS) is the largest oil spill in US history,
negatively impacting Gulf Coast residents and the surrounding ecosystem. To date, no studies …

Background Ovarian cancer incidence differs substantially by race/ethnicity, but the reasons
for this are not well understood. Data were pooled from the African American Cancer …

… Cushing-Haugen and Lauren C. Peres completed all data analysis, and Lauren C. Peres
drafted the manuscript. All authors contributed to and approved the final version of the …

… Peres and Tworoger developed the original concept and study design. Dr. Peres completed
all data analyses. Drs. Peres and Ms. Sinha generated the initial draft of the manuscript. All …

Most patients with multiple myeloma experience disease relapse after treatment with a B-cell
maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients …